Talis Biomedical Corp Performance
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Talis Biomedical are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Talis Biomedical Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable forward indicators, Talis Biomedical is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Begin Period Cash Flow | 130.2 M |
Talis |
Talis Biomedical Relative Risk vs. Return Landscape
If you would invest (100.00) in Talis Biomedical Corp on April 22, 2025 and sell it today you would earn a total of 100.00 from holding Talis Biomedical Corp or generate -100.0% return on investment over 90 days. Talis Biomedical Corp is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Talis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Talis Biomedical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Talis Biomedical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Talis Biomedical Corp, and traders can use it to determine the average amount a Talis Biomedical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
TLIS |
Based on monthly moving average Talis Biomedical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Talis Biomedical by adding Talis Biomedical to a well-diversified portfolio.
Talis Biomedical Fundamentals Growth
Talis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Talis Biomedical, and Talis Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Talis Pink Sheet performance.
Return On Equity | -0.7 | ||||
Return On Asset | -0.3 | ||||
Operating Margin | (113.60) % | ||||
Current Valuation | (38.24 M) | ||||
Shares Outstanding | 1.82 M | ||||
Price To Book | 0.06 X | ||||
Price To Sales | 19.57 X | ||||
Revenue | 412 K | ||||
EBITDA | (60.7 M) | ||||
Cash And Equivalents | 165.37 M | ||||
Cash Per Share | 6.21 X | ||||
Total Debt | 19.67 M | ||||
Debt To Equity | 0.19 % | ||||
Book Value Per Share | 26.68 X | ||||
Cash Flow From Operations | (53.24 M) | ||||
Earnings Per Share | (28.02) X | ||||
Total Asset | 98.34 M | ||||
Retained Earnings | (539.96 M) | ||||
Things to note about Talis Biomedical Corp performance evaluation
Checking the ongoing alerts about Talis Biomedical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Talis Biomedical Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Talis Biomedical is not yet fully synchronised with the market data | |
Talis Biomedical has some characteristics of a very speculative penny stock | |
Talis Biomedical has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 412 K. Net Loss for the year was (62.01 M) with loss before overhead, payroll, taxes, and interest of (149.4 M). | |
Talis Biomedical Corp currently holds about 165.37 M in cash with (53.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.21. |
- Analyzing Talis Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Talis Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining Talis Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Talis Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Talis Biomedical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Talis Biomedical's pink sheet. These opinions can provide insight into Talis Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Talis Pink Sheet
If you are still planning to invest in Talis Biomedical Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talis Biomedical's history and understand the potential risks before investing.
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |